Table 1

Comparison of clinical and pathological data of patients with anti-GBM disease with and without glomerular C1q deposition
With C1q deposition (n = 7) Without C1q deposition (n = 18) p
Age (years) 43.7 ± 11.8 27.2 ± 11.9 0.005
Gender (male/female) 6/1 16/2 1.000
Hydrocarbon exposure 1/7 (14.3%) 2/16 (12.5%) 1.000
Prodromal infection 2/7 (28.6%) 8/18 (44.4%) 0.653
Smoker 3/7 (42.9%) 8/18 (44.4%) 1.000
Hemoptysis 4/7 (57.1%) 8/18 (44.4%) 0.673
Oliguria/anuria 4/7 (57.1%) 10/18 (55.6%) 1.000
Gross hematuria 6/7 (85.7%) 6/18 (33.3%) 0.03
Nephrotic syndrome 2/3 (66.7%) 4/8 (50%) 1.000
Serum creatinine (μmol/L) 914.3 ± 161.3 1021.3 ± 402.9 0.353
Interval from onset (days) 48.6 ± 40.0 48.5 ± 33.3 0.998
Level of anti-GBM antibodies (U/mL) 88.0 ± 49.9 88.8 ± 43.0 0.969
ANCA positive 1/7 (14.3%) 1/18 (5.6%) 0.490
Hemoglobin (g/L) 89.6 ± 25.1 78.2 ± 29.5 0.377
Percentage of crescents in glomeruli (%) 91.0 (77.0-100.0) 100 (88.3-100.0) 0.386
 Cellular crescents (%) 75.0 (50.0-100.0) 75.0(24.5-89.5) 0.389
 Fibrocellular crescents (%) 25.0 (0–50) 25.0 (10.5-70.0) 0.336
 Fibrotic crescents (%) 0 0 0.961
Anti-C1q antibody positive 4/7 (57.1%) 11/18 (61.1%) 1.000
Level of anti-C1q antibodies (relative OD value) 0.210 ± 0.05 0.245 ± 0.06 0.301
Renal survival (1 year) 0/7 (0) 2/18 (11.1%) 1.000
Patient survival (1 year) 3/7 (42.9%) 15/18 (83.3%) 0.066

GBM Glomerular basement membrane, ANCA Anti-neutrophil cytoplasmic antibodies.

Hu et al.

Hu et al. BMC Immunology 2013 14:42   doi:10.1186/1471-2172-14-42

Open Data